相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Comparative Efficacy and Safety of Peficitinib 25, 50, 100, and 150 mg in Patients with Active Rheumatoid Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Young Ho Lee et al.
CLINICAL DRUG INVESTIGATION (2020)
Exportin 1 Inhibition Induces Nerve Growth Factor Receptor Expression to Inhibit the NF-κB Pathway in Preclinical Models of Pediatric High-Grade Glioma
John A. DeSisto et al.
MOLECULAR CANCER THERAPEUTICS (2020)
Clinical Pharmacokinetics and Pharmacodynamics of Imipenem-Cilastatin/Relebactam Combination Therapy
Matthew W. McCarthy
CLINICAL PHARMACOKINETICS (2020)
Selinexor (KTP-330)-a selective inhibitor of nuclear export (SINE): anti-tumor activity in diffuse large B-cell lymphoma (DLBCL)
Sharon Ben-Barouch et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2020)
An overview of lefamulin for the treatment of community acquired bacterial pneumonia
Vicenc Falco et al.
EXPERT OPINION ON PHARMACOTHERAPY (2020)
Current and future role of fedratinib in the treatment of myelofibrosis
Monica Ragheb et al.
FUTURE ONCOLOGY (2020)
Diastereoselective FeCl3•6H2O/NaBH4 Reduction of Oxime Ether for the Synthesis of β-Lactamase Inhibitor Relebactam
John Y. L. Chung et al.
JOURNAL OF ORGANIC CHEMISTRY (2020)
Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene-Related Peptide Receptor
Eric Moore et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2020)
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial
Gregory L. Krauss et al.
LANCET NEUROLOGY (2020)
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials
Alexander Drilon et al.
LANCET ONCOLOGY (2020)
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
Ying C. Ou et al.
LEUKEMIA & LYMPHOMA (2020)
Cenobamate for focal seizures - a game changer?
Jacqueline A. French
NATURE REVIEWS NEUROLOGY (2020)
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Shanu Modi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Review of Synthetic Routes and Crystalline Forms of the Antiandrogen Oncology Drugs Enzalutamide, Apalutamide, and Darolutamide
David L. Hughes
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2020)
Imipenem-Cilastatin-Relebactam: A Novel β-Lactam-β-Lactamase Inhibitor Combination for the Treatment of Multidrug-Resistant Gram-Negative Infections
Jordan R. Smith et al.
PHARMACOTHERAPY (2020)
Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Review for the Otolaryngologist
Saangyoung E. Lee et al.
AMERICAN JOURNAL OF RHINOLOGY & ALLERGY (2020)
Design, synthesis, antitumor activity and theoretical calculation of novel PI3Ka inhibitors
Ru-Yi Jin et al.
BIOORGANIC CHEMISTRY (2020)
The COVID-19 and Cancer Consortium: A Collaborative Effort to Understand the Effects of COVID-19 on Patients with Cancer Comment
Samuel M. Rubinstein et al.
CANCER CELL (2020)
Treatment of Patients with Relapsed or Refractory Mantle-Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase
Yuqin Song et al.
CLINICAL CANCER RESEARCH (2020)
Safety and Efficacy of Ubrogepant for the Acute Treatment of Episodic Migraine: A Meta-Analysis of Randomized Clinical Trials
Yanbo Yang et al.
CNS DRUGS (2020)
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled Trial
Mala Dharmalingam et al.
DRUGS (2020)
Synthetic Approaches to New Drugs Approved during 2018
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Quizartinib, a selective FLT3 inhibitor, maintains antileukemic activity in preclinical models of RAS-mediated midostaurin-resistant acute myeloid leukemia cells
Tomoya Aikawa et al.
Oncotarget (2020)
Highly Enantioselective, Hydrogen-Bond-Donor Catalyzed Additions to Oxetanes
Daniel A. Strassfeld et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2020)
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon et al.
NATURE (2020)
Cystic fibrosis 2019: Year in review
Iolo Doull
PAEDIATRIC RESPIRATORY REVIEWS (2020)
New drug approvals for 2019: Synthesis and clinical applications
Shuo Yuan et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Faping Wang et al.
MAYO CLINIC PROCEEDINGS (2020)
Process Development of Sotagliflozin, a Dual Inhibitor of Sodium-Glucose Cotransporter-1/2 for the Treatment of Diabetes
Matthew M. Zhao et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2020)
Enfortumab vedotin to treat urothelial carcinoma
K. S. Hanna
DRUGS OF TODAY (2020)
Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab
M. L. Amaya et al.
DRUGS OF TODAY (2020)
Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multi-centre, double-blind, randomised, placebo-controlled, dose-response trial (vol 19, pg 38, 2020)
G. L. Krauss et al.
LANCET NEUROLOGY (2020)
Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives
Chiara Maria Assunta Cefalo et al.
CARDIOVASCULAR DIABETOLOGY (2019)
The Latest Research and Development into the Antibody-Drug Conjugate, [fam-] Trastuzumab Deruxtecan (DS-8201a), for HER2 Cancer Therapy
Takashi Nakada et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2019)
Efficacy and Safety of Intravenous-to-oral Lefamulin, a Pleuromutilin Antibiotic, for the Treatment of Community-acquired Bacterial Pneumonia: The Phase III Lefamulin Evaluation Against Pneumonia (LEAP 1) Trial
Thomas M. File et al.
CLINICAL INFECTIOUS DISEASES (2019)
Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
George G. Zhanel et al.
DRUGS (2019)
Randomized phase 3 evaluation of trifarotene 50 μg/g cream treatment of moderate facial and truncal acne
Jerry Tan et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
The journey from gene knockout to clinical medicine: telotristat and sotagliflozin
Marc S. Rendell
DRUG DESIGN DEVELOPMENT AND THERAPY (2019)
Peficitinib: First Global Approval
Anthony Markham et al.
DRUGS (2019)
Synthetic Approaches to the New Drugs Approved During 2017
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3)
Yoshiya Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan
Tsutomu Takeuchi et al.
ANNALS OF THE RHEUMATIC DISEASES (2019)
Evaluation and use of an anti-cynomolgus monkey CD79b surrogate antibody-drug conjugate to enable clinical development of polatuzumab vedotin
Dongwei Li et al.
BRITISH JOURNAL OF PHARMACOLOGY (2019)
Inhibitors of nuclear transport
David A. Jans et al.
CURRENT OPINION IN CELL BIOLOGY (2019)
Entrectinib: First Global Approval
Zaina T. Al-Salama et al.
DRUGS (2019)
Remogliflozin Etabonate: First Global Approval
Anthony Markham
DRUGS (2019)
Effects of cenobamate (YKP3089), a newly developed anti-epileptic drug, on voltage-gated sodium channels in rat hippocampal CA3 neurons
Michiko Nakamura et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2019)
Efficacy and safety of lasmiditan in patients using concomitant migraine preventive medications: findings from SAMURAI and SPARTAN, two randomized phase 3 trials
Li Shen Loo et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap et al.
LANCET (2019)
Solriamfetol for the treatment of excessive daytime sleepiness associated with narcolepsy
Junyi Yang et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam
Pratik Bhagunde et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
Advances in potential treatment options for myeloproliferative neoplasm associated myelofibrosis
Prithviraj Bose
EXPERT OPINION ON ORPHAN DRUGS (2019)
Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
Takafumi Sato et al.
CLINICAL INFECTIOUS DISEASES (2019)
Sotagliflozin: A Review in Type 1 Diabetes
Emma D. Deeks
DRUGS (2019)
Elexacaftor/Ivacaftor/Tezacaftor: First Approval
Sheridan M. Hoy
DRUGS (2019)
Leave it to Lefamulin: A Pleuromutilin Treatment Option in Community-Acquired Bacterial Pneumonia
Young Ran Lee et al.
DRUGS (2019)
Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
Masutaka Furue et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Patent Review of Synthetic Routes and Crystalline Forms of the CFTR-Modulator Drugs Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor
David L. Hughes
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2019)
Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer's disease model
Elizabeth Spangenberg et al.
NATURE COMMUNICATIONS (2019)
In Vitro Activity of the New β-Lactamase Inhibitors Relebactam and Vaborbactam in Combination with β-Lactams against Mycobacterium abscessus Complex Clinical Isolates
Amit Kaushik et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Double-Blind Randomized Phase 3 Study Comparing Esaxerenone (CS-3150) and Eplerenone in Patients With Essential Hypertension (ESAX-HTN Study)
Sadayoshi Ito et al.
HYPERTENSION (2019)
Ubrogepant for the Treatment of Migraine
David W. Dodick et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Relugolix for the treatment of uterine fibroids
F. Barra et al.
DRUGS OF TODAY (2019)
A review of sotagliflozin for use in type 1 diabetes
Wesley Nuffer et al.
THERAPEUTIC ADVANCES IN ENDOCRINOLOGY AND METABOLISM (2019)
Efficacy and safety of sotagliflozin in treating diabetes type 1
Marc S. Rendell
EXPERT OPINION ON PHARMACOTHERAPY (2018)
Analgesic mechanisms of gabapentinoids and effects in experimental pain models: a narrative review
M. Chincholkar
BRITISH JOURNAL OF ANAESTHESIA (2018)
Ion Channel Modulators in Cystic Fibrosis
Martina Gentzsch et al.
CHEST (2018)
Cefiderocol (S-649266), A new siderophore cephalosporin exhibiting potent activities against Pseudomonas aeruginosa and other gram-negative pathogens including multi-drug resistant bacteria: Structure activity relationship
Toshiaki Aoki et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2018)
A phase III study evaluating the efficacy and safety of remimazolam (CNS 7056) compared with placebo and midazolam in patients undergoing colonoscopy
Douglas K. Rex et al.
GASTROINTESTINAL ENDOSCOPY (2018)
Phosphatidylinositol 3-Kinase -Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
Dejan Juric et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Synthetic Approaches to New Drugs Approved During 2016
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Kinase Inhibitors for the Treatment of Immunological Disorders: Recent Advances
Marian C. Bryan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Binding Characteristics and Analgesic Effects of Mirogabalin, a Novel Ligand for the α2δ Subunit of Voltage-Gated Calcium Channels
Yuki Domon et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2018)
Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy
Philip R. Holland et al.
NEUROTHERAPEUTICS (2018)
Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic
Michael P. Veve et al.
PHARMACOTHERAPY (2018)
The Orexin/Receptor System: Molecular Mechanism and Therapeutic Potential for Neurological Diseases
Chunmei Wang et al.
FRONTIERS IN MOLECULAR NEUROSCIENCE (2018)
Sickle cell disease
Gregory J. Kato et al.
NATURE REVIEWS DISEASE PRIMERS (2018)
In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group
Yuka Yamagishi et al.
ANAEROBE (2018)
Discovery and structural characterization of peficitinib (ASP015K) as a novel and potent JAK inhibitor
Hisao Hamaguchi et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2018)
RDX5791, a First-in-Class Minimally Systemic NHE3 Inhibitor in Clinical Development for CIC and IBS-C, Increases Intestinal Sodium Leading to Enhanced Intestinal Fluid Volume and Transit
Andrew G. Spencer et al.
GASTROENTEROLOGY (2018)
Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials
Samantha Meltzer-Brody et al.
LANCET (2018)
Advances in pharmaceutical treatment options for narcolepsy
Tatsunori Takahashi et al.
EXPERT OPINION ON ORPHAN DRUGS (2018)
Solriamfetol for the treatment of daytime sleepiness in obstructive sleep apnea
Vivien C. Abad et al.
EXPERT REVIEW OF RESPIRATORY MEDICINE (2018)
In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)
Julie M. Parmentier et al.
BMC RHEUMATOLOGY (2018)
Comparative pharmacokinetics of three SGLT-2 inhibitors sergliflozin, remogliflozin and ertugliflozin: an overview
Ranjeet Prasad Dash et al.
XENOBIOTICA (2017)
Mineralocorticoid receptor antagonists: 60 years of research and development
Peter Kolkhof et al.
JOURNAL OF ENDOCRINOLOGY (2017)
Neuroactive Steroids. 2.3 alpha-Hydroxy-3 beta-methyl-21-(4-cyano-1H-pyrazol-1 '-yl)-19-nor-5 beta-pregnan-20-one (SAGE-217): A Clinical Next Generation Neuroactive Steroid Positive Allosteric Modulator of the (gamma-Aminobutyric Acid)(A) Receptor
Gabriel Martinez Botella et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Synthetic Approaches to the New Drugs Approved During 2015
Andrew C. Flick et al.
JOURNAL OF MEDICINAL CHEMISTRY (2017)
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial
Stephen Kanes et al.
LANCET (2017)
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence
Biagio Ricciuti et al.
MEDICAL ONCOLOGY (2017)
Discovery and Pharmacological Characterization of JNJ-42756493 (Erdafitinib), a Functionally Selective Small-Molecule FGFR Family Inhibitor
Timothy P. S. Perera et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Discovery of GBT440, an Orally Bioavailable R-State Stabilizer of Sickle Cell Hemoglobin
Brian Metcalf et al.
ACS MEDICINAL CHEMISTRY LETTERS (2017)
In Vitro Activities and Spectrum of the Novel Fluoroquinolone Lascufloxacin (KRP-AM1977)
Ryuta Kishii et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Synthetic approaches to the 2014 new drugs
Andrew C. Flick et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2016)
Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads
Takashi Nakada et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
GBT440 increases haemoglobin oxygen affinity, reduces sickling and prolongs RBC half-life in a murine model of sickle cell disease
Donna Oksenberg et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Entrectinib is a potent inhibitor of Trk-driven neuroblastomas in a xenograft mouse model
Radhika Iyer et al.
CANCER LETTERS (2016)
DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1
Yusuke Ogitani et al.
CLINICAL CANCER RESEARCH (2016)
Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis
Emma D. Deeks
DRUGS (2016)
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Robert E. Davis et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Use of a dose-response model to guide future clinical trials of benvitimod cream to treat mild and moderate psoriasis
Yan-Nan Zang et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2016)
Discovery of Entrectinib: A New 3-Aminoindazole As a Potent Anaplastic Lymphoma Kinase (ALK), c-ros Oncogene 1 Kinase (ROS1), and Pan-Tropomyosin Receptor Kinases (Pan-TRKs) inhibitor
Maria Menichincheri et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
ITI-007 in the treatment of schizophrenia: from novel pharmacology to clinical outcomes
Robert E. Davis et al.
EXPERT REVIEW OF NEUROTHERAPEUTICS (2016)
Synthetic approaches to the 2013 new drugs
Hong X. Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2015)
Synthesis and Evaluation of 1H-Pyrrolo[2,3-b]pyridine Derivatives as Novel Immunomodulators Targeting Janus Kinase 3
Yutaka Nakajima et al.
CHEMICAL & PHARMACEUTICAL BULLETIN (2015)
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)
Meir Bialer et al.
EPILEPSY RESEARCH (2015)
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
Kiyoshi Arai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Remogliflozin etabonate: a novel SGLT2 inhibitor for treatment of diabetes mellitus
Nasser Mikhail
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Tenapanor hydrochloride for the treatment of constipation-predominant irritable bowel syndrome
Marta Zielińska et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Entrectinib: a potent new TRK, ROS1, and ALK inhibitor
Christian Rolfo et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Discovery of (1R,2S)-2-{[(2,4-Dimethylpyrimidin-5-yl)oxy]methy1}-2-(3-fluorophenyl)-N-(5-fluoropyridin-2-yl)cyclopropanecarboxamide (E2006): A Potent and Efficacious Oral Orexin Receptor Antagonist
Yu Yoshida et al.
JOURNAL OF MEDICINAL CHEMISTRY (2015)
Insomnia disorder
Charles M. Morin et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Design, Synthesis and Antimicrobial Evaluation of Novel Tricyclic Benzoxazine Fluoroquinolones under Conventional and Microwave Methods
B. Guruswamy et al.
JOURNAL OF HETEROCYCLIC CHEMISTRY (2015)
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
Anu-Maarit Moilanen et al.
SCIENTIFIC REPORTS (2015)
Synthetic approaches to the 2012 new drugs
Hong X. Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2014)
Mutational Analysis of PI3K/AKT Signaling Pathway in Tamoxifen Exemestane Adjuvant Multinational Pathology Study
Vicky S. Sabine et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Discovery of a Tetracyclic Quinoxaline Derivative as a Potent and Orally Active Multifunctional Drug Candidate for the Treatment of Neuropsychiatric and Neurological Disorders
Peng Li et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
N-Boc Deprotection and Isolation Method for Water-Soluble Zwitterionic Compounds
Zhijian Liu et al.
JOURNAL OF ORGANIC CHEMISTRY (2014)
The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke's Encephalopathy
Qiang Zhang et al.
DRUG METABOLISM AND DISPOSITION (2014)
Synthetic approaches to the 2011 new drugs
Hong X. Ding et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2013)
Design and synthesis of tricyclic cores for kinase inhibition
Stacy Van Epps et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation
Pascal Furet et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator
Shifeng Pan et al.
ACS MEDICINAL CHEMISTRY LETTERS (2013)
Synthetic approaches to the 2010 new drugs
Kevin K. -C. Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Non-Systemic Drugs: A Critical Review
Dominique Charmot
CURRENT PHARMACEUTICAL DESIGN (2012)
Highly Selective Primary Alkoxycarboxylation and Esterification of Unprotected Pyranose Derivatives Mediated by Scandium(III) Triflate Catalysis
Michael S. McClure et al.
EUROPEAN JOURNAL OF ORGANIC CHEMISTRY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Large-Scale Carbonyl Reductions in the Pharmaceutical Industry
Javier Magano et al.
ORGANIC PROCESS RESEARCH & DEVELOPMENT (2012)
Assessment of the Drug Interaction Risk for Remogliflozin Etabonate, a Sodium-Dependent Glucose Cotransporter-2 Inhibitor: Evidence from In Vitro, Human Mass Balance, and Ketoconazole Interaction Studies
James F. Sigafoos et al.
DRUG METABOLISM AND DISPOSITION (2012)
Orexin Receptors: Pharmacology and Therapeutic Opportunities
Thomas E. Scammell et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 51, 2011 (2011)
Synthetic approaches to the 2009 new drugs
Kevin K. -C. Liu et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2011)
Discovery of 1-{4[1-(2,6-Difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl]-3-methoxyurea (TAK-385) as a Potent, Orally Active, Non-Peptide Antagonist of the Human Gonadotropin-Releasing Hormone Receptor
Kazuhiro Miwa et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
A Concise Synthesis of a β-Lactamase Inhibitor
Ian K. Mangion et al.
ORGANIC LETTERS (2011)
Enhancement of GABAergic Activity: Neuropharmacological Effects of Benzodiazepines and Therapeutic Use in Anesthesiology
Teijo I. Saari et al.
PHARMACOLOGICAL REVIEWS (2011)
Synthesis and Structure-Activity Studies of Biphenyl Analogues of the Tuberculosis Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Brian D. Palmer et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
A Concise and Convergent Synthesis of PA-824
Maurice A. Marsini et al.
JOURNAL OF ORGANIC CHEMISTRY (2010)
Synthetic Approaches to the 2008 New Drugs
Kevin K.-C. Liu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2010)
Synthesis, Crystal Structure, and Spectral Characterization of Flumatinib Mesylate
Gang Xu et al.
SYNTHETIC COMMUNICATIONS (2010)
PREPARATION OF STEROID SULFAMATES AND THEIR INTERACTION WITH GABA(A) RECEPTOR
Vojtech Kapras et al.
COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS (2009)
Synthesis, Reduction Potentials, and Antitubercular Activity of Ring A/B Analogues of the Bioreductive Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824)
Andrew M. Thompson et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Identification of N-(5-tert-Butyl-isoxazol-3-yl)-N′-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl}urea Dihydrochloride (AC220), a Uniquely Potent, Selective, and Efficacious FMS-Like Tyrosine Kinase-3 (FLT3) Inhibitor
Qi Chao et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Bacterial biosynthesis of a multipotent stilbene
Susan A. Joyce et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2008)
Synthetic Approaches to the 2007 New Drugs
Kevin K. -C. Liu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2008)
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Ramandeep Singh et al.
SCIENCE (2008)
Synthetic approaches to the 2006 new drugs
Kevin K. -C. Liu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2007)
Integration of solventless reaction in a multi-step process: Application to an efficient synthesis of PA-824
Akihiro Orita et al.
ADVANCED SYNTHESIS & CATALYSIS (2007)
Synthetic approaches to the 2005 new drugs
Subas M. Sakya et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2007)
On the mechanism of an asymmetric α,β-unsaturated carboxylic acid hydrogenation:: Application to the synthesis of a PGD2 receptor antagonist
David M. Tellers et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2006)
Identification of a nitroimidazo-oxazine-specific protein involved in PA-824 resistance in Mycobacterium tuberculosis
UH Manjunatha et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Synthetic approaches to the 2004 new drugs
J Li et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2005)
Olanzapine: a critical review of recent literature
PF Buckley
EXPERT OPINION ON PHARMACOTHERAPY (2005)
Androgen receptor in prostate cancer
CA Heinlein et al.
ENDOCRINE REVIEWS (2004)
Androgen receptor: A key molecule in the progression of prostate cancer to hormone independence
ME Taplin et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2004)
Synthetic approaches to the 2002 new drugs
J Li et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2004)
Claisen rearrangement over the past nine decades
AMM Castro
CHEMICAL REVIEWS (2004)
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
SO Doronina et al.
NATURE BIOTECHNOLOGY (2003)
Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position:: A highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor
S Sasaki et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Molecular biology of the androgen receptor
EP Gelmann
JOURNAL OF CLINICAL ONCOLOGY (2002)
Modification of C-terminal peptides to form peptide enamides: Synthesis of chondriamides A and C
X Wang et al.
JOURNAL OF ORGANIC CHEMISTRY (2001)
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
CK Stover et al.
NATURE (2000)
分享论文
